Thomas/Wyden Medicare Rx Plan Has Royalty On Federally Funded Research

Pharmaceutical companies would be required to pay a "return on investment fee" from profits on drugs that benefited from federal research funding under a Medicare drug benefit proposal outlined May 26 by Rep. Thomas (R-Calif.) and Sen. Wyden (D-Ore.).